



Published in final edited form as:

Genes Chromosomes Cancer. 2018 March ; 57(3): 140–149. doi:10.1002/gcc.22512.

Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery

Yue Hu¹, Jochen Gaedcke², Georg Emons^{1,2}, Tim Beissbarth³, Marian Grade², Peter Jo², Meredith Yeager⁴, Stephen J. Chanock⁴, Hendrik Wolff⁵, Jordi Camps¹, B. Michael Ghadimi², and Thomas Ried¹

¹Section of Cancer Genomics, Genetics Branch, National Cancer Institute, Bethesda, MD 20892, USA

²Department of General, Visceral and Pediatric Surgery, University Medical Center, 37075 Göttingen, Germany

³Department of Medical Statistics, University Medical Center, 37075 Göttingen, Germany

⁴Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA

⁵Department of Radiation Oncology, University Medical Center, 37075 Göttingen, Germany

Abstract

To understand the molecular mechanism of rectal cancer and develop markers for disease prognostication, we generated and explored a dataset from 243 rectal cancer patients by gene expression microarray analysis of cancer samples and matched controls, and SNP-arrays of germline DNA. We found that two of the loci most strongly linked with colorectal cancer (CRC) risk, 8q24 (upstream of *MYC*) and 18q21 (in the intron of *SMAD7*), as well as 20q13 (in the intron of *LAMA5*), are tightly associated with the prognosis of rectal cancer patients. For SNPs on 18q21 (rs12953717 and rs4464148) and 20q13 (rs4925386), alleles that correlate with higher risk for the development of CRC are associated with shorter disease free survival (DFS). However, for rs6983267 on 8q24, the low risk allele is associated with a higher risk for recurrence and metastasis after surgery, and importantly, is strongly correlated with the resistance of CRC cell lines to chemoradiotherapy (CRT). We also found that although *MYC* expression is dramatically increased in cancer, patients with higher levels of *MYC* have a better prognosis. The expression of *SMAD7* is weakly correlated with DFS. Notably, the presence of the 8q24 and 18q21 SNP alleles is not correlated with expression levels of *MYC* and *SMAD7*. rs4464148, and probably rs6983267 and rs4925386, are linked with overall survival time of patients. In conclusion, we show that several CRC risk SNPs detect subpopulations of rectal cancer patients with poor prognosis, and that rs6983267 probably affects prognosis through interfering with the resistance of cancer cells to CRT.

Correspondence to: Thomas Ried, MD, Center for Cancer Research, National Cancer Institute, Building 50, Room 1408, Bethesda, MD 20892-8010, riedt@mail.nih.gov.

Conflict of interest:
None.

Keywords

colorectal cancer; rectal cancer; SNP; MYC; prognosis

Introduction

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death in the USA. Each year there are more than 130,000 new cases and more than 49,000 deaths from CRC (Ferlay, et al. 2015). Rectal cancers account for some 35% of all CRC cases (American Cancer Society 2016). Despite similarities in the genetic aberrations profiles rectal cancer and colon cancer from microsatellite stable (MSS) patients show significant differences in clinical outcome. Anatomic differences also influence the treatment of these cancers. While colon cancers are usually surgically removed and then treated with adjuvant chemotherapy, the standard treatment for locally advanced rectal cancers consists of a preoperative chemoradiotherapy (CRT) (Rodel, et al. 2012a; Sauer, et al. 2004) followed by a total mesorectal excision of the tumor. Furthermore, the typical site of metastasis or progression is different: colon cancers metastasize primarily to liver and have a tendency to spread to the peritoneum, while distal rectal cancers often surpass the liver and spread to the lung (Riihimaki, et al. 2016). Molecular and genetic studies as well reveal both remarkable similarities but also some noteworthy distinctions. For example, *APC* mutations occur with higher frequency in rectal cancer than in colon cancer (Hong, et al. 2012; van der Sijp, et al. 2016).

Many genome-wide association studies (GWAS) have successfully identified more than 20 SNPs associated with the risk for the development of CRC (reviewed in Peters, et al. 2013; Zhang, et al. 2014). As outlined above, colon and rectal cancers are very different in their clinical behavior. To our knowledge, the prognostic value of these SNPs has not been systematically evaluated in rectal cancer patients. Here we analyze an extensive dataset of rectal cancers to identify if any of these SNPs are also associated with outcome in rectal cancer patients. SNPs associated with prognosis might augment already established clinical tests and could help to individualize a patients' treatment.

The most extensively studied risk locus of cancer is the SNP rs6983267 on chromosome band 8q24. The G allele of rs6983267 increases the risk of developing several cancers, including CRC, prostate cancer and breast cancer (Haiman, et al. 2007; Jones, et al. 2012). Several hypotheses have been proposed to explain the effect of rs6983267, including enhanced binding of the WNT pathway transcription factor TCF7L2 in the *MYC* promoter region, hence activating transcription (Pomerantz, et al. 2009; Wright, et al. 2010). Another possible mechanism of action might be interference with the expression of the noncoding RNA CCAT2 and CARLo-5 (Kim, et al. 2014; Ling, et al. 2013). The second most studied risk locus on 18q21 contains three SNPs: rs4939827, rs12953717 and rs4464148. They map to introns of the tumor suppressor gene *SMAD7* (Curtin, et al. 2009; Tenesa, et al. 2008), influencing its expression. *SMAD7* is involved in the regulation of the TGF- β pathway (Luo, et al. 2014).

In this study, we explore whether the SNPs that affect the risk of the development of CRC also alter the prognosis of rectal cancer patients and whether their presence affects the expression of adjacent genes.

Materials and Methods

Patients

Overall, 243 patients were included in this analysis. 230 patients could be included in the survival analysis (Supplementary table 1). All patients were staged as locally advanced (cUICCII/III/IV) and treated according to the CAO/ARO/AIO-94 (Sauer, et al. 2004) or the CAO/ARO/AIO-04 trial (Rodel, et al. 2012b). Staging included rigid rectoscopy and endorectal ultrasonography, magnetic resonance imaging (MRI) and/or computed tomography as well as patho-histological diagnosis of an adenocarcinoma. Preoperative staging was performed as clinically assessed T-level (T), lymph node status (N) and distant metastases (M). The results were unified as clinical UICC stage (UICC) (Brierley, et al. 2009).

Staging and treatment was either performed in Göttingen (n=165) or at the five collaborating German Departments of Surgery or Radioncology (n=65). Preoperative chemoradiotherapy (CRT) was applied with a total irradiation dose of 50.4 Gray (28×1.8 Gray) and accompanied by either 5-fluorouracil infusion alone (n=128) or in combination with oxaliplatin (n=102). Six weeks after the completion of preoperative CRT, curative surgery (total mesorectal excision) was performed. Standardized histopathological work-up resulted in histopathological parameters of T-level and lymph node status. If distant metastases developed during preoperative CRT a biopsy for histopathological analysis was taken if possible. Four to six weeks after surgery therapy was completed with either 5-FU alone or in combination with oxaliplatin. Recurrence refers to detection of local recurrence or metastasis. The study was approved by the local ethics committee.

Tumor Biopsies, RNA/DNA Isolation

During rectoscopy several biopsies of tumor and matched normal mucosa were taken in addition to the diagnostic sample, as well as EDTA-blood as previously described (Gaedcke, et al. 2012). For gene expression analyses biopsies were immediately stored in RNAlater and kept at 4°C over night. The following day biopsies were frozen and stored at -20°C. Blood was centrifuged (2200 rpm, 10min at 4°C), plasma and the cellular components (leukocyte phase) were aliquoted and stored at -80°C.

Using TRIZOL (Life Technologies, Rockville, MD, USA) RNA was extracted from RNAlater biopsies as previously described (Grade, et al. 2011). All samples underwent strict quality assessment. Nucleic acid quantity and purity were determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), and by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). For SNP analyses, after informed consent, 7.5 ml of fresh blood was collected, anti-coagulated by EDTA and centrifuged for 10 min at 2000 rpm, and the plasma carefully removed. Samples were stored at -80 °C until isolation. DNA was isolated using the Blood and Tissue DNA midi kit

(Qiagen) according to manufacture's instruction. Briefly, after adding 100 µl of proteinase K to 1 ml of each sample cells were lysed by adding 1.2 ml of Buffer AL, vortexed and incubated for 10 min at 70°C. DNA was bound to a DNeasy spin column and washed. DNA was eluted in water and stored at 20°C until further use. DNA quantity and quality were assessed using Nanodrop and Bioanalyzer.

Gene Expression Microarray Analysis

Microarrays analysis was performed as previously described (Grade, et al. 2011). Briefly, 600ng of total RNA was amplified and transcribed into fluorescently labeled cRNA following the "Low RNA Input linear Amplification Kit Plus, One Color" protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339). cRNA was hybridized to the Human 4 × 44 K v2 array platform from Agilent Technologies (G4845A) as recommended by the manufacturer. Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA). In total there are cancer samples from 216 patients with qualified microarray data. 170 of them also have qualified microarray data of normal mucosa samples. 203 of them have clinical data (Supplementary table 1).

The Bioconductor package arrayQualityMetrics was used to determine the quality of microarray data. The signal intensities from the gene expression arrays were log2 transformed before being normalized to the 75 percentile as instructed by the Agilent protocol. Probes with maximum intensity over all samples of at least 100 were used for further analysis. Gene fold change of each cancer sample was calculated with paired normal mucosa sample as reference if available, otherwise the geometric average intensity of all normal samples was used as reference. Gene expression data were deposited to Gene Expression Omnibus (GSE87211).

Illumina Infinium HD assay

High-throughput, genome-wide SNP genotyping, using Infinium Human1M-Quadv1 technology (Part 15003560; Illumina Inc. San Diego, CA), was performed at the Cancer Genomics Research Laboratory (CGR), NCI. Genotyping was performed according to the manufacturer's guidelines using the Infinium HD Assay automated protocol. Samples were denatured and neutralized then isothermally amplified by whole-genome amplification. The amplified product was enzymatically fragmented, then precipitated and re-suspended before hybridization to the BeadChip. Single-base extension of the oligos on the BeadChip, using the captured DNA as a template, incorporates tagged nucleotides on the BeadChip, which are subsequently fluorophore labeled during staining. The fluorescent label determines the genotype call for the sample. The Illumina iScan scanned the BeadChips at two wavelengths to create image files. Genotypes were called using Illumina GenomeStudio software and exported for analysis.

Statistical analysis

Microarray data from rectal cancer sample of 216 patients are used in expression analysis. 196 of them with clinical data, including 49 cases of recurrence and/or metastasis after

surgery and 28 case of death due to rectal cancer, are included in survival analysis associated with gene expression. 183 rectal cancer patients have SNP data (Supplementary Table 3). 178 of them with clinical follow up, including 45 cases of recurrence and/or metastasis after surgery and 27 case of death due to rectal cancer, are included in survival analysis associated with SNP alleles.

A change of gene expression with a threshold of 3-fold change (either up or down) and a P value of 0.05 in two tailed unpaired t-test after multiple test correction was considered to be significant. The list of genes, the expression of which significantly differed between the cancer and the mucosa control, was used for Ingenuity Pathway Analysis (IPA) (Qiagen, Hilden, Germany) in Supplementary Table 2 using the standard methods. The false discovery rate is the adjusted P value with Benjamini–Hochberg method.

PCA (Principal Component Analysis) of gene expression was conducted utilizing Partek Genomics Suite (Partek Inc, Chesterfield, MO) for log2 transformed intensity (Figure 1A) or log2 fold change (Figure 1B-I). Data points of patient 93 and patient 195 samples were removed in Figure 1B-I to get an extensive view of the whole group.

Survival curves were constructed using the Kaplan–Meier method and analyzed by the log-rank test. If an event occurred, the survival interval is the period between the surgery and the time of event. If the patient died without an event, the data is censored at the time of death. Otherwise the data is censored at the last clinical assessment. Survival data were evaluated using the univariate and multivariate Cox proportional hazards model. Only variables with a significant value of $P < 0.05$ in univariate analysis were used in the construction of subsequent multivariate Cox models. Cox P value is used unless otherwise stated. Samples were separated into two groups of equal size for high and low gene expression.

The SNPs tested in this study influence CRC occurrence at very different strengths (Broderick, et al. 2007; Houlston, et al. 2008; Tomlinson, et al. 2007). From biological intuition, a factor's ability to increase CRC risk is likely to be correlated to its potential effect on recurrence risk, and such an inequality will invalidate the assumption of multiple test correction. This inequality can be revealed by enrichment analysis. Among 3 loci with significant effect on rectal cancer recurrence, two are localized on the no.1 and no.3 locus with highest CRC risk in the total list of 21 loci. The biased distribution $P < 0.028$ confirmed the significant association between CRC risk and recurrence risk. With this confirmed inequality, multiple test correction was not applied for SNP number in this study.

Results

Global gene expression changes are neither associated with survival, lymph node metastasis and depth of invasion, nor with *KRAS* mutation status

The Principal Component Analysis (PCA) of expression data distinguishes cancer samples clearly from control samples, illustrating the drastic change of gene expression patterns during tumorigenesis. As expected, the normal controls cluster more tightly together than the tumor samples (Figure 1A). The list of genes significantly up-regulated in tumors relative to mucosa is enriched for genes associated with WNT- β catenin signaling. Genes

significantly down-regulated are linked particularly with various metabolic pathways (Supplementary Table 2). The general expression pattern of cancer samples forms no apparent subgroups (Figure 1B), and there is no separation according to any prognostic parameters, including lymph node metastasis or depth of invasion before or after preoperative CRT, *KRAS* mutation status, disease free survival (DSF) or overall survival (OS) of the patients (Figure 1C-I). Consistently, differential expression analysis for any of those prognostic parameters, e.g., comparison between cancer samples with or without *KRAS* mutations, revealed no statistically significant differences in gene expression (data not shown). Lymph node metastasis and depth of invasion scores from biopsies after, but not before CRT, show a significant association with DSF and OS (Table 2, Supplementary Figure 1A-D, F-I). *KRAS* mutation status serves as an established biomarker for treatment with EGFR inhibitors, such as panitumumab and cetuximab. Only patients with tumors that do not harbor *KRAS* mutations benefit from anti-EGFR therapy (Cunningham, et al. 2004). Our data show that the *KRAS* mutation status cannot predict response to neoadjuvant chemoradiotherapy (Table 2, Supplementary Figure 1 E, J).

Association of polymorphisms and interval to recurrence after surgery

Many GWAS of CRC have identified polymorphisms in at least 22 loci associated with an increased risk of developing CRC. We investigated the association of 21 of those loci with DSF and OS. We found three loci that are significantly associated with rectal cancer recurrence, including rs6983267 on 8q24 upstream of *MYC*, rs12953717 and rs4464148 on 18q21 in an intron of *SMAD7*, and rs4925386 on 20q13 in an intron of *LAMA5* (Table 1). The SNP rs4464148 on 18q21 also has a significant effect on OS, while the SNP rs6983267 on 8q24 ($P = 0.076$) and the SNP rs4925386 on 20q13 ($P = 0.053$) have noticeable effect although not significant (Table 1). 8q24 and 18q21 are among the loci with the most significant P value for CRC risk (Table 1) (Whiffin, et al. 2014). Interestingly, rs6983267 has opposite effects when analyzed for CRC susceptibility and prognosis. The high-risk allele G of rs6983267 correlates with an increase in CRC incidence in the population, but is associated with a longer DSF and OS for rectal cancer patients when compared to the low-risk allele T (Table 1). We have investigated the difference in sensitivity of CRC cell lines to CRT (Spitzner, et al. 2014). We found that the CRT sensitivities of CRC cell lines are tightly correlated with their rs6983267 genotypes. Cell lines with higher CRT resistance invariably carry the T allele that is associated with short DSF in rectal cancer patients (Figure 2F). Such an allelic specific distribution is not observed for any other significant SNPs (Supplementary Figure 2).

Allele G of rs6983267 enhances CRC incidence with a dosage effect; this fits with an additive model (Li, et al. 2008), while CRC recurrence of patients carrying the allele T fits best with a dominant model; thus, patients with the GT allele have survival curves very similar to the TT allele (DSF: HR = 2.21, 95% CI 1.03–4.74, $P = 0.042$) (Figure 2A). In contrast, the high-risk alleles for CRC occurrence and recurrence are the same for rs12953717 and rs4464148 (Table 1). The 18q21 SNP rs12953717 (DSF: HR = 2.46, 95% CI 1.11–5.5; $P = 0.039$) and the 20q13 SNP rs4925386 (DSF: HR = 0.43, 95% CI 0.24–0.79; $P = 0.007$) fit best with the dominant and recessive model, respectively (Figure 2B,E), while the 18q21 SNP rs4464148 fits best with the additive model for both DSF and OS, with a 1.8-

fold hazard risk for DSF (95% CI 1.19-2.72; $P = 0.005$) (Figure 2C) and 1.87-fold hazard risk for OS (95% CI 1.11-3.13; $P = 0.019$) (Supplementary Figure 4C) for each high-risk allele. Multivariate Cox analysis shows only depth of invasion (ypT) and distant metastasis (M) after CRT as significant predictors of DSF (Table 2).

After multiple test correction, we did not detect any significantly differentially expressed genes among samples with different rs6983267 genotypes (data not shown). However, we discovered that, under a loose criterion of t test P value < 0.05 with no correction for multiple testing, the expression of two radioresistance related genes, *NOS1* and *AATK* (Epperly, et al. 2007; Rajagopalan, et al. 2010; Zhu, et al. 2016), is correlated with allele number and has a P value < 0.05 between homozygous alleles (Supplementary Figure 3). In line with their reported effect on radioresistance, the expression of both *NOS1* and *AATK* have the lowest expression in samples with TT alleles, intermediate expression in samples with GT alleles, and highest expression in samples with GG alleles.

Association between prognosis and the expression of genes adjacent to SNPs associated with CRC

We examined the expression of genes potentially linked with the SNPs on 8q24, 18q21 and 20q13, which are *MYC*, *SMAD7* and *LAMA5*, respectively. Our data show no correlation between their expression levels and the presence of specific SNPs (Figure 3D-H). In addition, the overall expression levels of these genes with respect to different alleles for any of these SNPs are indistinguishable from each other (data not shown). But *MYC*, and to a lesser extent *SMAD7*, do have an association with prognosis. Compared to matched normal mucosa, rectal cancers have significantly higher expression of *MYC* and lower expression of *SMAD7* (Figure 3A-B). However, patients with lower *MYC* expression or higher *SMAD7* expression have shorter DSF and probably shorter OS, though the P value is only significant for effect of *MYC* expression on DSF (HR = 0.49, 96% CI 0.27-0.88; $P = 0.017$) (Figure 4A-B). *LAMA5* expression is consistently increased in cancer samples (Figure 3C), but it is not correlated with prognosis (Figure 4C, 4F). These results were confirmed with independent CRC sample sets (Supplementary Figure 5).

Discussion

Previous GWAS studies have identified dozens of loci associated with an increased risk for the development of CRC (Peters, et al. 2013; Zhang, et al. 2014). In this study we determined whether those loci affect the prognosis of patients with rectal cancers, which comprise approximately 35% of patients with CRC (Society 2016). We did observe that three loci, on chromosome bands 8q24, 18q21 and 20q13, significantly influence DSF, and to a lesser extent, OS. It is reasonable to assume that genetic factors that increase the risk for cancer development could also affect disease prognostication. Consistently, we found that two out of these three loci (8q24 and 18q21) are among the loci with strongest association with CRC risk (significance rank no.1 and no.3 respectively in the GWAS study of Houlston 2008). They are also the 1st and 2nd loci found associated with colorectal cancer (Broderick, et al. 2007; Houlston, et al. 2008; Tomlinson, et al. 2007). Both loci are associated with

highly significant P value in many GWAS (Peters, et al. 2015) and are the two most extensively studied CRC risk loci.

rs6983267 on 8q24 has been found to be strongly associated with multiple cancer types, including CRC (Haiman, et al. 2007), prostate cancer (Yeager, et al. 2007), and thyroid cancer (Jones, et al. 2012). Interestingly, 8q24 SNP rs6983267 has divergent effects on CRC occurrence and prognosis. This is reminiscent of the effect of *BRCA1/2* mutations on breast cancer risk, which is significantly increased in women carrying these mutations. But they correlate with longer DSF and OS time in patients with triple negative breast cancers (Anders, et al. 2013). Such a reverse association of rs6983267 is also found in prostate cancer, where the G allele correlates with the risk of cancer occurrence, while the T allele is significantly associated with metastatic prostate cancer, with 1.49 risk ratio over the G allele (Ahn, et al. 2011). The fact that rectal cancer and prostate cancer share such a phenomenon suggests a common mechanism. One possible mechanism is that the G allele of rs6983267 lowers the threshold for genetic changes that result in CRC occurrence, such that patients with the G allele tend to accumulate fewer mutations and genomic imbalances when the tumor is detectable, and thus have a better prognosis. It will be interesting to see if this phenomenon holds true in the other cancer types influenced by rs6983267, such as thyroid and breast cancers.

Intriguingly, the CRT resistance levels of CRC cell lines are tightly correlated with the genotype of rs6983267 SNP such that cell lines with homozygous GG alleles are always more CRT sensitive than cell lines carrying GT alleles. This discovery suggests that the apparent adverse effect of the T allele in rectal and prostate cancer patients might be due to its role in increasing the CRT resistance of cancer cells. Radiosensitivity related genes with allelic differential expression such as *NOS1* and *AATK* might contribute to this effect. Cells derived from *NOS1* homozygous knockout mouse have significantly enhanced radioresistance (Epperly, et al. 2007; Rajagopalan, et al. 2010). *AATK* siRNA knockdown promotes cell line survival after ionizing radiation while its overexpression has the opposite consequence (Zhu, et al. 2016). Consistently, *NOS1* and *AATK* have the lowest expression in rectal cancer samples with TT homozygous alleles, and highest expression in samples with homozygous GG alleles. (Supplementary Figure 3). This effect might also arise from allele-related differences in general expression response to CRT, which could be revealed by a future meta-analysis of post-CRT samples.

Rectal cancer samples have greatly increased expression levels of *MYC* compared to matched normal mucosa, while the expression of *SMAD7* is consistently decreased; however, patients with higher *MYC* expression or lower *SMAD7* expression show a better prognosis than patients with an opposite expression pattern (see below).

The SNPs on 18q21 locus also correlates with prognosis. But unlike rs6983267, the alleles on 18q21, rs4939827, rs12953717 and rs4464148 have the same effect on CRC risk and recurrence of patients with rectal cancer. These three SNPs are in the same intron of *SMAD7* and are in high linkage disequilibrium (Li, et al. 2008; Thompson, et al. 2009). We found that the alleles of rs12953717 and rs4464148 are significantly associated with DSF. The 3rd SNP, rs4939827, shows the same trend, although with an insignificant P value, likely

due to the limited sample size (Figure 2B, Table 1). Not surprisingly, the directions of the effects on DSF are the same as on OS for those SNPs affecting both DSF and OS (rs4464148, rs6983267 and rs4925386).

The three loci correlated with prognosis of rectal cancer patients are adjacent to *MYC*, *SMAD7* and *LAMA5*, respectively. *MYC* is involved both in hematological malignancies and solid tumors, and is required for oncogenesis in a mouse model of CRC (Ignatenko, et al. 2006; Sansom, et al. 2007). *MYC* is also an important regulator of cancer stem cells (Curry, et al. 2015). Cancer stem cells are significantly more resistant to CRT than the bulk tumor and are thought to be responsible for cancer recurrence after therapy (Krause, et al. 2017). One conceivable mechanism is that the long-term effect of rs6983267 on *MYC* expression perturbs the stemness of cells and results in a differential response of cancer cells to CRT. We found that the majority of CRC cancer samples have dramatically higher expression of *MYC* (>80% samples with >2 fold increase and >50% with >4 fold increase Figure 3F), probably due to aberrant Wnt/ β -catenin signaling (Rennoll and Yochum 2015). Surprisingly, again we found that the expression level of *MYC* is reversely correlated with tumor aggressiveness; patients with high *MYC* expression having a longer DSF after surgery. rs6983267 has been reported to enhance binding of the transcription factor TCF7L2 to the enhancer of *MYC* (Rosse, et al. 2014; Verzi, et al. 2010). One could hypothesize that rs6983267 exerts its effect on CRC by directly interfering with *MYC* expression level. However, the expression level of *MYC* in both mucosa and tumor tissues is not correlated with rs6983267 alleles (Figure 3A), even when normalized to genomic copy numbers of this locus (data not shown). This result does not rule out the possibility that the presence of rs6983267 influences CRC risk via an alteration of *MYC* expression during a transient but important period of tumorigenesis, but this change, if it exists, is masked by other process at later stages of CRC that drastically increase *MYC* expression.

SMAD7 is involved in tumorigenesis and metastasis (Halder, et al. 2005; Halder, et al. 2008). The samples analyzed in the present data set show dramatically decreased levels of *SMAD7* expression when compared to matched normal mucosa. *SMAD7* expression levels showed a weak correlation with prognosis (Figure 3J, Supplementary Figure 5B). Intriguingly, patients with lower *SMAD7* expression have a longer DSF. The result is consistent with the finding that loss of *SMAD7* is associated with a favorable outcome for CRC patients, while amplification of *SMAD7* worsens survival (Boulay, et al. 2003). Therefore, for both *MYC* and *SMAD7*, the change in expression in cancer comparing with control tissue is reversely correlated with DSF. Our data show that there is no direct correlation between the alleles of SNPs and the expression of these genes in tumor samples (Figure 3A-D) or control samples (data not shown). In addition, the presence of different alleles (high-risk or low-risk) does not determine global gene expression levels (data not shown). It therefore remains to be determined on how precisely these SNPs influence cancer risk.

In summary, our results suggest that polymorphisms at specific SNPs on chromosome bands 8q24, 18q21 and 20q13 hold promise as clinically useful tools to predict therapy outcomes and long term follow-up of rectal cancer patients. It will be informative to study the correlation between these SNPs and other CRC prognostic factors and to study whether

there exists a differential response to various treatments used in patients with CRC depending on the presence of distinct alleles. These studies will provide a deeper understanding of the molecular mechanisms underlying the idiosyncrasies of individual tumor behavior and disease outcome, and hopefully will help to develop evidence-based individualized treatments.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported in part by the Intramural Research Program, NCI/NIH. The authors are grateful to Dr. Reinhard Ebner for critical comments on the manuscript.

References

- Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, Stanford JL, Ostrander EA, Chanock S, Wang MH, Mittal RD, Isaacs WB, Platz EA, Hayes RB. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. *Clin Cancer Res*. 2011; 17(5):1075–1081. [PubMed: 21343373]
- American Cancer Society. Colorectal Cancer Facts & Figures 2014-2016. Colorectal Cancer Facts & Figures publications; 2016.
- Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. *Hematol Oncol Clin North Am*. 2013; 27(4):737–749. viii. [PubMed: 23915742]
- Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C. SMAD7 is a prognostic marker in patients with colorectal cancer. *Int J Cancer*. 2003; 104(4):446–449. [PubMed: 12584741]
- Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours (7th). 2009
- Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Consortium C. Kerr D, Gray R, Peto J, Cazier JB, Tomlinson I, Houlston RS. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. *Nat Genet*. 2007; 39(11):1315–1317. [PubMed: 17934461]
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med*. 2004; 351(4):337–345. [PubMed: 15269313]
- Curry EL, Moad M, Robson CN, Heer R. Using induced pluripotent stem cells as a tool for modelling carcinogenesis. *World J Stem Cells*. 2015; 7(2):461–469. [PubMed: 25815129]
- Curtin K, Lin WY, George R, Katory M, Shorto J, Cannon-Albright LA, Bishop DT, Cox A, Camp NJ. Meta association of colorectal cancer confirms risk alleles at 8q24 and 18q21. *Cancer Epidemiol Biomarkers Prev*. 2009; 18(2):616–621. [PubMed: 19155440]
- Epperly MW, Cao S, Zhang X, Franicola D, Shen H, Greenberger EE, Epperly LD, Greenberger JS. Increased longevity of hematopoiesis in continuous bone marrow cultures derived from NOS1 (nNOS, mtNOS) homozygous recombinant negative mice correlates with radioresistance of hematopoietic and marrow stromal cells. *Exp Hematol*. 2007; 35(1):137–145.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015; 136(5):E359–386. [PubMed: 25220842]

- Gaedcke J, Grade M, Camps J, Sokilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Moller S, Beissbarth T, Ried T, Litman T. The rectal cancer microRNAome—microRNA expression in rectal cancer and matched normal mucosa. *Clin Cancer Res.* 2012; 18(18):4919–4930. [PubMed: 22850566]
- Grade M, Hummon AB, Camps J, Emons G, Spitzner M, Gaedcke J, Hoermann P, Ebner R, Becker H, Difilippantonio MJ, Ghadimi BM, Beissbarth T, Caplen NJ, Ried T. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. *Int J Cancer.* 2011; 128(5):1069–1079. [PubMed: 20473941]
- Haiman CA, Le Marchand L, Yamamoto J, Stram DO, Sheng X, Kolonel LN, Wu AH, Reich D, Henderson BE. A common genetic risk factor for colorectal and prostate cancer. *Nat Genet.* 2007; 39(8):954–956. [PubMed: 17618282]
- Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. *Exp Cell Res.* 2005; 307(1):231–246. [PubMed: 15922743]
- Halder SK, Rachakonda G, Deane NG, Datta PK. Smad7 induces hepatic metastasis in colorectal cancer. *Br J Cancer.* 2008; 99(6):957–965. [PubMed: 18781153]
- Hong TS, Clark JW, Haigis KM. Cancers of the colon and rectum: identical or fraternal twins? *Cancer Discov.* 2012; 2(2):117–121. [PubMed: 22585856]
- Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, Spain SL, Broderick P, Domingo E, Farrington S, Prendergast JG, Pittman AM, Theodoratou E, Smith CG, Olver B, Walther A, Barnetson RA, Churchman M, Jaeger EE, Penegar S, Barclay E, Martin L, Gorman M, Mager R, Johnstone E, Midgley R, Niittymaki I, Tuupanen S, Colley J, Idziaszczyk S, Thomas HJ, Lucassen AM, Evans DG, Maher ER, Maughan T, Dimas A, Dermitzakis E, Cazier JB, Aaltonen LA, Pharoah P, Kerr DJ, Carvajal-Carmona LG, Campbell H, Dunlop MG, Tomlinson IP. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. *Nat Genet.* 2010; 42(11):973–977. [PubMed: 20972440]
- Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, Chandler I, Vijayakrishnan J, Sullivan K, Penegar S, Carvajal-Carmona L, Howarth K, Jaeger E, Spain SL, Walther A, Barclay E, Martin L, Gorman M, Domingo E, Teixeira AS, Kerr D, Cazier JB, Niittymaki I, Tuupanen S, Karhu A, Aaltonen LA, Tomlinson IP, Farrington SM, Tenesa A, Prendergast JG, Barnetson RA, Cetnarskyj R, Porteous ME, Pharoah PD, Koessler T, Hampe J, Buch S, Schafmayer C, Tepel J, Schreiber S, Volzke H, Chang-Claude J, Hoffmeister M, Brenner H, Zanke BW, Montpetit A, Hudson TJ, Gallinger S, Campbell H, Dunlop MG. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. *Nat Genet.* 2008; 40(12):1426–1435. [PubMed: 19011631]
- Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, de Alboranc IM, Guillen RJ, Gerner EW. Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse. *Cancer Biol Ther.* 2006; 5(12):1658–1664. [PubMed: 17106247]
- Jones AM, Howarth KM, Martin L, Gorman M, Mihai R, Moss L, Auton A, Lemon C, Mehanna H, Mohan H, Clarke SE, Wadsley J, Macias E, Coatesworth A, Beasley M, Roques T, Martin C, Ryan P, Gerrard G, Power D, Bremmer C, Consortium T, Tomlinson I, Carvajal-Carmona LG. Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24. *J Med Genet.* 2012; 49(3):158–163. [PubMed: 22282540]
- Kim T, Cui R, Jeon YJ, Lee JH, Lee JH, Sim H, Park JK, Fadda P, Tili E, Nakanishi H, Huh MI, Kim SH, Cho JH, Sung BH, Peng Y, Lee TJ, Luo Z, Sun HL, Wei H, Alder H, Oh JS, Shim KS, Ko SB, Croce CM. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. *Proc Natl Acad Sci U S A.* 2014; 111(11):4173–4178. [PubMed: 24594601]
- Krause M, Dubrovskaya A, Linge A, Baumann M. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. *Adv Drug Deliv Rev.* 2017; 109:63–73. [PubMed: 26877102]
- Li L, Plummer SJ, Thompson CL, Merkulova A, Acheson LS, Tucker TC, Casey G. A common 8q24 variant and the risk of colon cancer: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev.* 2008; 17(2):339–342. [PubMed: 18268117]

- Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafa R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Res.* 2013; 23(9):1446–1461. [PubMed: 23796952]
- Luo L, Li N, Lv N, Huang D. SMAD7: a timer of tumor progression targeting TGF-beta signaling. *Tumour Biol.* 2014; 35(9):8379–8385. [PubMed: 24935472]
- Peters U, Bien S, Zubair N. Genetic architecture of colorectal cancer. *Gut.* 2015; 64(10):1623–1636. [PubMed: 26187503]
- Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, Chan AT, Chang-Claude J, Chanock SJ, Chen LS, Coetzee GA, Coetzee SG, Conti DV, Curtis KR, Duggan D, Edwards T, Fuchs CS, Gallinger S, Giovannucci EL, Gogarten SM, Gruber SB, Haile RW, Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Hopper JL, Hudson TJ, Hunter DJ, Jackson RD, Jee SH, Jenkins MA, Jia WH, Kolonel LN, Kooperberg C, Kury S, Lacroix AZ, Laurie CC, Laurie CA, Le Marchand L, Lemire M, Levine D, Lindor NM, Liu Y, Ma J, Makar KW, Matsuo K, Newcomb PA, Potter JD, Prentice RL, Qu C, Rohan T, Rosse SA, Schoen RE, Seminara D, Shrubsole M, Shu XO, Slaterry ML, Taverna D, Thibodeau SN, Ulrich CM, White E, Xiang Y, Zanke BW, Zeng YX, Zhang B, Zheng W, Hsu L. Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. *Gastroenterology.* 2013; 144(4):799–807.e724. [PubMed: 23266556]
- Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. *Nat Genet.* 2009; 41(8):882–884. [PubMed: 19561607]
- Rajagopalan MS, Stone B, Rwigema JC, Salimi U, Epperly MW, Goff J, Franicola D, Dixon T, Cao S, Zhang X, Buchholz BM, Bauer AJ, Choi S, Bakkenist C, Wang H, Greenberger JS. Intraesophageal manganese superoxide dismutase-plasmid liposomes ameliorates novel total-body and thoracic radiation sensitivity of NOS1^{-/-} mice. *Radiat Res.* 2010; 174(3):297–312. [PubMed: 20726721]
- Rennoll S, Yochum G. Regulation of MYC gene expression by aberrant Wnt/beta-catenin signaling in colorectal cancer. *World J Biol Chem.* 2015; 6(4):290–300. [PubMed: 26629312]
- Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. *Sci Rep.* 2016; 6:29765. [PubMed: 27416752]
- Rodel C, Hofheinz R, Liersch T. Rectal cancer: state of the art in 2012. *Curr Opin Oncol.* 2012a; 24(4):441–447. [PubMed: 22450150]
- Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sulberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Kohler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, German Rectal Cancer Study G. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol.* 2012b; 13(7): 679–687. [PubMed: 22627104]
- Rosse SA, Auer PL, Carlson CS. Functional annotation of putative regulatory elements at cancer susceptibility Loci. *Cancer Inform.* 2014; 13(Suppl 2):5–17. [PubMed: 25288875]
- Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR. Myc deletion rescues Apc deficiency in the small intestine. *Nature.* 2007; 446(7136): 676–679. [PubMed: 17377531]
- Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study

- G. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med*. 2004; 351(17):1731–1740. [PubMed: 15496622]
- Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. *Gastroenterology*. 2010; 138(3):958–968. [PubMed: 19914252]
- Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, Rave-Frank M, Kramer F, Beissbarth T, Kitz J, Wienands J, Ghadimi BM, Ebner R, Ried T, Grade M. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. *Int J Cancer*. 2014; 134(4): 997–1007. [PubMed: 23934972]
- Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, Barnetson RA, Theodoratou E, Cetnarskyj R, Cartwright N, Semple C, Clark AJ, Reid FJ, Smith LA, Kavoussanakis K, Koessler T, Pharoah PD, Buch S, Schafmayer C, Tepel J, Schreiber S, Volzke H, Schmidt CO, Hampe J, Chang-Claude J, Hoffmeister M, Brenner H, Wilkening S, Canzian F, Capella G, Moreno V, Deary IJ, Starr JM, Tomlinson IP, Kemp Z, Howarth K, Carvajal-Carmona L, Webb E, Broderick P, Vijayakrishnan J, Houlston RS, Rennert G, Ballinger D, Rozek L, Gruber SB, Matsuda K, Kidokoro T, Nakamura Y, Zanke BW, Greenwood CM, Rangrej J, Kustra R, Montpetit A, Hudson TJ, Gallinger S, Campbell H, Dunlop MG. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat Genet*. 2008; 40(5):631–637. [PubMed: 18372901]
- Thompson CL, Plummer SJ, Acheson LS, Tucker TC, Casey G, Li L. Association of common genetic variants in SMAD7 and risk of colon cancer. *Carcinogenesis*. 2009; 30(6):982–986. [PubMed: 19357349]
- Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Consortium C. Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. *Nat Genet*. 2007; 39(8):984–988. [PubMed: 17618284]
- Tuupainen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Bjorklund M, Wei G, Yan J, Niittymäki I, Mecklin JP, Jarvinen H, Ristimäki A, Di-Bernardo M, East P, Carvajal-Carmona L, Houlston RS, Tomlinson I, Palin K, Ukkonen E, Karhu A, Taipale J, Aaltonen LA. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. *Nat Genet*. 2009; 41(8):885–890. [PubMed: 19561604]
- van der Sijp MP, Bastiaannet E, Mesker WE, van der Geest LG, Breugom AJ, Steup WH, Marinelli AW, Tseng LN, Tollenaar RA, van de Velde CJ, Dekker JW. Differences between colon and rectal cancer in complications, short-term survival and recurrences. *Int J Colorectal Dis*. 2016; 31(10): 1683–1691. [PubMed: 27497831]
- Verzi MP, Hatzis P, Sulahian R, Phillips J, Schuijers J, Shin H, Freed E, Lynch JP, Dang DT, Brown M, Clevers H, Liu XS, Shivdasani RA. TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions. *Proc Natl Acad Sci U S A*. 2010; 107(34): 15157–15162. [PubMed: 20696899]
- Whiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, Zgaga L, Lloyd A, Kinnersley B, Gorman M, Tenesa A, Broderick P, Wang Y, Barclay E, Hayward C, Martin L, Buchanan DD, Win AK, Hopper J, Jenkins M, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Liu T, Campbell H, Lindblom A, Houlston RS, Tomlinson IP, Dunlop MG. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. *Hum Mol Genet*. 2014; 23(17):4729–4737. [PubMed: 24737748]
- Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. *Mol Cell Biol*. 2010; 30(6):1411–1420. [PubMed: 20065031]
- Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin

- G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat Genet.* 2007; 39(5):645–649. [PubMed: 17401363]
- Zhang K, Civan J, Mukherjee S, Patel F, Yang H. Genetic variations in colorectal cancer risk and clinical outcome. *World J Gastroenterol.* 2014; 20(15):4167–4177. [PubMed: 24764655]
- Zhu RX, Song CH, Yang JS, Yi QT, Li BJ, Liu SH. Downregulation of AATK mediates microRNA-558-induced resistance of A549 cells to radiotherapy. *Mol Med Rep.* 2016; 14(3): 2846–2852. [PubMed: 27485693]




Figure 1. Principal component analysis (PCA) of expression levels of rectal cancer samples and matched normal mucosa

PCA of gene expression of both control samples (green) and rectal cancer samples (red) (A), of expression fold change of rectal cancer samples compared with paired controls (B-I). Samples with (C) RAS mutation (red) or without mutation (green), with lymph node metastasis (red) or without (green) before (D) or after (E) CRT, (F) with depth of invasion before CRT including T2 (green), T3 (yellow) or T4 (crimson), (G) with depth of invasion after CRT including T0 (green), T1 (blue), T2 (yellow), T3 (red) or T4 (crimson), (H) with recurrence after surgery (red) or disease free (green), (I) death due to CRC (red) or survival (green).




Figure 2. Influence of CRC development associated SNPs on DFS of rectal cancer patients and on CRT resistance of CRC cell lines
Kaplan-Meier curves of DSF of 8q24 SNP rs6983267 (A), 18q21 SNPs rs12953717 (B) rs4464148 (C) and rs4939827 (D), 20q13 SNP rs4925386 (E) for rectal cancer patients. (F) Genotype of rs6983267 for CRC cell lines. Cell lines are ordered according to their CRT resistance as in Spitzner, et al. (2014) Figure C. Genotypes unfavorable to rectal cancer patients are highlighted with gray. See supplementary figure 2 for data of all 5 SNPs.




Figure 3. Expressions levels of *MYC*, *SMAD7* and *LAMA5* have no association with adjacent significant SNPs

Fold change of expression of *MYC* (A), *SMAD7* (B) and *LAMA4* (C) of rectal cancer samples comparing with paired controls. Expression of *MYC* in cancer samples with different alleles of rs6983267 (D), *SMAD7* with different alleles of rs12953717 (E) rs4464148 (F) and rs4939827 (G) and *LAMA5* with different alleles of rs4925386 (H). One way Anova P value was calculated.




Figure 4. Low *MYC* expression is significantly associated with disease free time of rectal cancer patients

Kaplan-Meier curves of disease free time of high and low expression of *MYC* (A), *SMAD7* (B) and *LAMA5* (C). Kaplan-Meier curves of survival of high and low expression of *MYC* (D), *SMAD7* (E) and *LAMA5* (F).

CRC occurrence risk loci and their association with disease free time and survival time of rectal cancer patients

Table 1

Loci are ordered according to P value associated with CRC occurrence from Houlston, et al. (2010) Houlston, et al. (2008) and Whiffin, et al. (2014). HR, CI 95% and P value are calculated with univariate Cox proportional hazard model. Significant P values (<0.05) are highlighted with bold. P value and HR calculation for dominant and recessive effect SNPs: rs6983267 TT+GT versus GG, rs4939827 TT+CT versus CC, rs12953717 TT+CT versus CC, rs4925386 TT+CT versus CC; for additive effect SNP rs4925386: TT=0, CT=1, CC=2; for other SNPs: CRC occurrence risky homozygous allele versus non-risky homozygous allele. SNP rs16892766 does not have enough CC allele samples for calculation. SNP rs647161 is not on the SNP array and its data is not available. SNP rs6687758 does not have a death case for the AA reference allele for survival time analysis. See supplementary table 4 for a complete list of P value and HR of CRC disease free time.

Cytoband	Gene	SNP	CRC occurrence			rectal cancer recurrence			rectal cancer survival		
			Risky allele	No-Risky allele	Risky allele	Genetic effect	HR (95% CI)	P	HR (95% CI)	P	P
8q24	MYC	rs6983267	G	T	T	dominant	2.21(1.03-4.74)	0.042	2.61(0.9-7.56)	0.08	
11q23	POU2AF1	rs3802842	C	A	A		0.94(2.45-0.36)	0.905	0.8(0.26-2.43)	0.69	
18q21	SMAD7	rs12953717	T	C	T	dominant	2.46(1.1-5.5)	0.029	1.38(0.56-3.43)	0.49	
		rs4464148	C	T	C	additive	1.8(1.19-2.72)	0.005	1.87(1.11-3.13)	0.02	
		rs4939827	T	C	T	dominant	2.11(0.83-5.35)	0.115	1.26(0.44-3.66)	0.67	
8q23	EIF3H	rs16892766	A	C	C		—	—	—	—	
15q13	GREM1	rs4779584	T	C	C		1.78(0.54-5.87)	0.346	3(0.87-10.42)	0.08	
19q13	RHPN2	rs10411210	C	T	T		1.35(0.19-9.84)	0.767	0.84(0.11-6.25)	0.86	
20p12	BMP2	rs961253	A	C	C		0.8(1.86-0.34)	0.6	0.56(1.92-0.16)	0.36	
16q22	CDH1	rs9929218	G	A	A		0.46(1.13-0.19)	0.089	0.95(4.22-0.22)	0.95	
14q22	BMP4	rs4444235	C	T	T		1.12(0.47-2.64)	0.796	0.88(0.25-3.14)	0.85	
11q13	POLD3	rs3824999	G	T	T		1.19(0.55-2.6)	0.658	0.69(0.23-2.07)	0.51	
10p14	FLJ3802842	rs10795668	G	A	A		2.44(0.58-10.37)	0.226	3.52(0.45-27.42)	0.23	
20q13	LAMA5	rs4925386	C	T	C	recessive	0.43(0.24-0.79)	0.007	0.46(0.21-1.01)	0.05	

Cytoband	Gene	SNP	CRC occurrence			rectal cancer recurrence			rectal cancer survival		
			Risky allele	No-Risky allele		Risky allele	Genetic effect	HR (95% CI)	P	HR (95% CI)	P
20p12	BMP2	rs4813802	G	T			1.18(0.46-2.99)	0.729	1.38(0.48-3.96)	0.56	
12q12	DIP2	rs11169552	C	T			1.97(0.47-8.3)	0.357	1.27(0.29-5.59)	0.76	
12q12	ATF1	rs7136702	T	C			1.1(0.4-3.03)	0.85	0.31(0.04-2.46)	0.27	
3q36	TERC	rs10936599	C	T			1.65(0.39-6.97)	0.498	2.29(0.3-17.53)	0.43	
20p12	HAO1	rs2423279	C	T			0.8(2.31-0.28)	0.679	0.99(3.4-0.29)	0.98	
1q41	DUSP10	rs6691170	T	G			1.16(0.5-2.69)	0.723	0.84(0.32-2.2)	0.72	
1q41	DUSP10	rs6687758	G	A			0.85(3.6-0.2)	0.827	—	—	
6p21	CDKN1A	rs1321311	A	C			0.5(3.66-0.07)	0.491	1.66(12.95-0.21)	0.63	
5q31	PITX1	rs647161	A	C			—	—	—	—	
12p13	CCND2	rs10774214	T	C			1.33(0.64-2.78)	0.447	0.96(0.36-2.52)	0.93	

CRC: Colorectal cancer

Table 2

Univariate and multivariate analyses of SNPs and clinicopathological variables for disease free time (Cox proportional hazards regression) Because of high linkage disequilibrium among 18q21 SNPs, only rs4464148 is included in multivariate analysis. Significant P values (<0.05) are highlighted in bold.

Variable	Category	Univariate analysis		Multivariate analysis	
		HR (95% CI)	P	HR (95% CI)	P
Age	>65 vs. ≤65	0.97(0.54-1.77)	0.932		
Sex	F vs. M	1.32(0.72-2.43)	0.377		
Kras status	mutant vs. WT	1.05(0.59-1.89)	0.866		
Neoadjuvant Therapy					
	5-FU + RT	1			
	5-FU + Oxaliplatin + Cetuximab + RT	—	—		
	5-FU + Oxaliplatin + RT	1.38(0.77-2.48)	0.278		
Depth of invasion before NT (T)	2-4	1.07(0.39-2.94)	0.889		
Lymph node metastasis before NT (N)	0-1	1.62(0.8-3.29)	0.179		
Distant metastasis (M) before NT	0-1	67.4(24.71-183.8)	2.2E-16	0.84(0.26-2.73)	0.766
Depth of invasion after NT (ypT)	0-4	2.16(1.5-3.12)	3.6E-05	1.8(1.21-2.68)	0.0036
Lymph node metastasis after NT (ypN)	0-2	2.03(1.38-2.98)	2.8E-04	1.05(0.66-1.66)	0.832
Distant metastasis (M) after NT	0-1	331.5(70.58-15571)	1.9E-13	181.5(28.14-1170)	4.5E-08
8q24	rs6983267	2.21(1.03-4.74)	0.042	1.31(0.59-2.94)	0.509
18q21	rs12953717	2.46(1.1-5.5)	0.029		
	rs4464148	1.8(1.19-2.72)	0.005	1.23(0.78-1.94)	0.368
	rs4939827	2.11(0.83-5.35)	0.115		
20q12	rs4925386	0.43(0.24-0.79)	0.007	0.59(0.31-1.12)	0.107